
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Sophia Antipolis, France - Galderma's commitment to dermatology, and dermatology only, is nowhere more evident than in its sprawling, approximately 24,000-square-foot research and development facility in the south of France.






